Skip to content


Monjuvi, Minjuvi (tafasitamab) is an antibody pharmaceutical. Tafasitamab was first approved as Monjuvi on 2020-07-31. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat large b-cell lymphoma diffuse. The pharmaceutical is active against B-lymphocyte antigen CD19.
Trade Name Minjuvi
Common Name Tafasitamab
Indication large b-cell lymphoma diffuse
Drug Class Monoclonal antibodies: tumors
Get full access now